RUA Life Sciences PLC
Company Profile
Business description
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
Contact
2 Drummond Crescent
Scotland
IrvineAyrshireKA11 5AN
GBRT: +44 1294317073
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2026
Employees
40
Stocks News & Analysis
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
stocks
Market is misinterpreting AI impact on cheap ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,408.70 | 27.40 | -0.29% |
| CAC 40 | 8,624.56 | 65.49 | 0.77% |
| DAX 40 | 25,290.99 | 115.05 | 0.46% |
| Dow JONES (US) | 49,467.74 | 14.41 | -0.03% |
| FTSE 100 | 10,822.36 | 15.95 | 0.15% |
| HKSE | 26,381.02 | 384.70 | -1.44% |
| NASDAQ | 22,788.47 | 363.61 | -1.57% |
| Nikkei 225 | 58,753.39 | 170.27 | 0.29% |
| NZX 50 Index | 13,670.71 | 145.13 | 1.07% |
| S&P 500 | 6,889.85 | 56.28 | -0.81% |
| S&P/ASX 200 | 9,175.30 | 27.60 | -0.30% |
| SSE Composite Index | 4,146.63 | 0.60 | -0.01% |